Home › Follicular Lymphoma › Massachusetts › Boston
Follicular Lymphoma clinical trials in Boston, MA
17 studies for Follicular Lymphoma are looking for participants at sites in and around Boston (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
RecruitingPhase 3
- Tufts Medical Center, Boston
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
RecruitingPhase 1/2
- Dana Farber Cancer Institute, Boston
Epco, Zanu, Ritux for R/R FL or MZL
RecruitingPhase 2
- Dana-Farber Cancer Institute, Boston
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
RecruitingPhase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RecruitingPhase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
RecruitingPhase 3
- Research Site, Boston
- Research Site, Boston
NEO100 and High-Grade Meningioma
RecruitingPhase 2
- Tufts Medical Center, Boston
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
RecruitingPhase 3
- Beth Israel Deaconess Medical Center, Boston
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
RecruitingPhase 3
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Epcoritamab and Rituximab for First-line Follicular Lymphoma
RecruitingPhase 2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
RecruitingPhase 3
- Local Institution - 0145, Boston
- Local Institution - 0244, Boston
- Local Institution - 0247, Boston
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
RecruitingPhase 1
- Massachusetts General Hospital, Boston
Odronextamab in Low Tumor Volume Advanced FL
RecruitingPhase 2
- Beth Israel Deaconess Medical Center, Boston
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RecruitingPhase 2
- Beth Israel Deaconess Medical Center, Boston
Study of SGR-1505 in Mature B-Cell Neoplasms
RecruitingPhase 1
- Beth Israel Deaconess Medical Center, Boston
A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
RecruitingPhase 1/2
- Dana Farber Cancer Institute, Boston
Emapalumab Prevention of CAR-T Cell Associated Toxicities
RecruitingPhase 2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Follicular Lymphoma trials in other cities
- New York City, NY24 studies
- Milwaukee, WI19 studies
- Nashville, TN18 studies
- Houston, TX18 studies
- Baldwin Park, CA16 studies
- Seattle, WA15 studies
- Durham, NC15 studies
- Columbus, OH13 studies
- Salt Lake City, UT13 studies
- Philadelphia, PA12 studies
- Chicago, IL12 studies
- San Antonio, TX12 studies
Other studies in Boston
- Breast Cancer111 studies
- Non-Small Cell Lung Cancer90 studies
- Cancer (all types)86 studies
- Colorectal Cancer63 studies
- Metastatic Cancer63 studies
- Lung Cancer62 studies
- Ovarian Cancer61 studies
- Prostate Cancer59 studies
- Depression52 studies
- Endometrial Cancer50 studies
- Heart Failure44 studies
- Acute Myeloid Leukemia44 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.